Napredna pretraga

Pregled bibliografske jedinice broj: 120878

Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers.


Veljača, Marija; Pavić-Sladoljev, D.; Mildner, Boris; Brajša, Karmen; Krnić, Žarka; Bubenik, M.; Stipaničić, S.; Tabak-Slošić, Maja; Brnić, L.; Khan, Z. et al.
Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. // Abstracts of the 6th ESGENA Conference and 10th United European Gastroentherology Week : UEGW u: European Journal of Pharmaceutical Sciences (ISSN 0928-0987) 17 (2002) (Sl)
Geneva, Švicarska, 2002. str. 74-75 (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers.

Autori
Veljača, Marija ; Pavić-Sladoljev, D. ; Mildner, Boris ; Brajša, Karmen ; Krnić, Žarka ; Bubenik, M. ; Stipaničić, S. ; Tabak-Slošić, Maja ; Brnić, L. ; Khan, Z. ; Krznarić, Željko ; Bischoff, A. ; Scroeder, A. ; van Dongen, W.D. ; van Schaik, F.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 6th ESGENA Conference and 10th United European Gastroentherology Week : UEGW u: European Journal of Pharmaceutical Sciences (ISSN 0928-0987) 17 (2002) (Sl) / - , 2002, 74-75

Skup
United European Gastroentherology Week (10 ; 2002)

Mjesto i datum
Geneva, Švicarska, 19.-22.102002

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
ulcerative colitis; PL 14736; phase I clinical testing

Sažetak
PL 14736, a novel 15 amino acid peptide, has shown benefical activity in experimental models of gastrointestinal damage. Seven-day intracolonic administration of PL 14736 to rats has significantly reduced the extent TNBS-induced colonic damage and hastened healing. These results have encuraged the development of the compound for the treatment of patients with ulcerative colitis. In this first study in man, rectal administration of PL 14736 to healthy male volunteers was safe and well tolerated. Based on these data, a randomized, double-blind, placebo-controlled study was started in order to investigate the tolerabillity and efficacy of Pl 14736 enemas in patients with acute mild to moderate ulcerative colitis

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove
Pliva-Istraživački institut

Citiraj ovu publikaciju

Veljača, Marija; Pavić-Sladoljev, D.; Mildner, Boris; Brajša, Karmen; Krnić, Žarka; Bubenik, M.; Stipaničić, S.; Tabak-Slošić, Maja; Brnić, L.; Khan, Z. et al.
Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. // Abstracts of the 6th ESGENA Conference and 10th United European Gastroentherology Week : UEGW u: European Journal of Pharmaceutical Sciences (ISSN 0928-0987) 17 (2002) (Sl)
Geneva, Švicarska, 2002. str. 74-75 (poster, međunarodna recenzija, sažetak, znanstveni)
Veljača, M., Pavić-Sladoljev, D., Mildner, B., Brajša, K., Krnić, Ž., Bubenik, M., Stipaničić, S., Tabak-Slošić, M., Brnić, L. & Khan, Z. (2002) Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers.. U: Abstracts of the 6th ESGENA Conference and 10th United European Gastroentherology Week : UEGW u: European Journal of Pharmaceutical Sciences (ISSN 0928-0987) 17 (2002) (Sl).
@article{article, year = {2002}, pages = {74-75}, keywords = {ulcerative colitis, PL 14736, phase I clinical testing}, title = {Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers.}, keyword = {ulcerative colitis, PL 14736, phase I clinical testing}, publisherplace = {Geneva, \v{S}vicarska} }